Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group
Top Cited Papers
- 10 June 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (17), 2094-2101
- https://doi.org/10.1200/jco.2011.38.9924
Abstract
Systemic exposure to mercaptopurine (MP) is critical for durable remissions in children with acute lymphoblastic leukemia (ALL). Nonadherence to oral MP could increase relapse risk and also contribute to inferior outcome in Hispanics. This study identified determinants of adherence and described impact of adherence on relapse, both overall and by ethnicity. A total of 327 children with ALL (169 Hispanic; 158 non-Hispanic white) participated. Medication event-monitoring system caps recorded date and time of MP bottle openings. Adherence rate, calculated monthly, was defined as ratio of days of MP bottle opening to days when MP was prescribed. After 53,394 person-days of monitoring, adherence declined from 94.7% (month 1) to 90.2% (month 6; P < .001). Mean adherence over 6 months was significantly lower among Hispanics (88.4% v 94.8%; P < .001), patients age ≥ 12 years (85.8% v 93.1%; P < .001), and patients from single-mother households (80.6% v 93.1%; P = .001). A progressive increase in relapse was observed with decreasing adherence (reference: adherence ≥ 95%; 94.9% to 90%: hazard ratio [HR], 4.1; 95% CI,1.2 to 13.5; P = .02; 89.9% to 85%: HR, 4.0; 95% CI, 1.0 to 15.5; P = .04; < 85%: HR. 5.7; 95% CI, 1.9 to 16.8; P = .002). Cumulative incidence of relapse (± standard deviation) was higher among Hispanics (16.5% ± 4.0% v 6.3% ± 2.2%; P = .02). Association between Hispanic ethnicity and relapse (HR, 2.6; 95% CI, 1.1 to 6.1; P = .02) became nonsignificant (HR, 1.8; 95% CI, 0.6 to 5.2; P = .26) after adjusting for adherence and socioeconomic status. At adherence rates ≥ 90%, Hispanics continued to demonstrate higher relapse, whereas at rates < 90%, relapse risk was comparable to that of non-Hispanic whites. Lower adherence to oral MP increases relapse risk. Ethnic difference in relapse risk differs by level of adherence—an observation currently under investigation.Keywords
This publication has 37 references indexed in Scilit:
- Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemiaNature Genetics, 2011
- Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemiaBlood, 2010
- Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: A retrospective cohort studyClinical Therapeutics, 2009
- Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort studyBMC Health Services Research, 2009
- Trends in childhood cancer incidence in the U.S. (1992–2004)Cancer, 2007
- Understanding Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: A ReviewJournal of Pediatric Hematology/Oncology, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- The Electronic Medication Event MonitorClinical Pharmacokinetics, 1997
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986
- Social desirability and response to perceived situational demands.Journal of Consulting Psychology, 1961